| Literature DB >> 9230204 |
H S Friedman1, S P Johnson, Q Dong, S C Schold, B K Rasheed, S H Bigner, F Ali-Osman, E Dolan, O M Colvin, P Houghton, G Germain, J T Drummond, S Keir, S Marcelli, D D Bigner, P Modrich.
Abstract
A methylator-resistant human glioblastoma multiforme xenograft, D-245 MG (PR), in athymic nude mice was established by serially treating the parent xenograft D-245 MG with procarbazine. D-245 MG xenografts were sensitive to procarbazine, temozolomide, N-methyl-N-nitrosourea, 1,3-bis(2-chloroethyl)-1-nitrosourea, 9-aminocamptothecin, topotecan, CPT-11, cyclophosphamide, and busulfan. D-245 MG (PR) xenografts were resistant to procarbazine, temozolomide, N-methyl-N-nitrosourea, and busulfan, but they were sensitive to the other agents. Both D-245 MG and D-245 MG (PR) xenografts displayed no O6-alkylguanine-DNA alkyltransferase activity, and their levels of glutathione and glutathione-S-transferase were similar. D-245 MG xenografts expressed the human mismatch repair proteins hMSH2 and hMLH1, whereas D-245 MG (PR) expressed hMLH1 but not hMSH2.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9230204
Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701